Skip to content

About Us
Products
Pipeline
News
- Company Updates
- Media
Careers
Contact

News

InterTrade

InterTrade Ireland All Island Venture Capital Conference

April 22nd 2024

Banner

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers

April 8th 2024April 8th 2024

Shorla Oncology

We are delighted to be attending the HOPA 2024 conference at Tampa Florida from 3-6 April. We are looking forward to meeting you at Booth #620.

March 26th 2024March 26th 2024

Shorla Oncology

Shorla Oncology Achieves Great Place to Work Certification

March 26th 2024

FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Pharmaceutical Executive/ FDA Accepts New Drug Application for Shorla Oncology’s Novel Treatment for Breast, Ovarian Cancer

January 29th 2024January 12th 2024

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for novel formulation to treat breast and ovarian cancer

January 9th 2024

Older posts

Newer posts

Page1 … Page7 Page8 Page9 … Page19

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology^®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY^® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress

About Us
Products
Pipeline
News
- Company Updates
- Media
Careers
Contact

Now approved for use in Pediatrics

Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.